Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13R?2-targeted CAR T-Cells in High-Grade Glioma
Stock Information for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
Loading
Please wait while we load your information from QuoteMedia.